Growth will be driven by a strong late-stage pipeline, which includes several highly valuable targeted therapies
The global dermatology market is set to experience strong growth from US$20bn in 2015 to $33.7bn by 2022, representing a compound annual growth rate of 7.7%, says business intelligence provider GBI Research.
According to the company’s latest report, such an impressive rise will occur in spite of the patent expiries of many marketed monoclonal antibodies (mAbs), which are unlikely to have a significant impact because of the practical and regulatory barriers faced by biosimilars.
Growth will be driven by a strong late-stage pipeline, which includes several highly valuable targeted therapies, such as dupilumab, AN-2729, AMG-827 and ixekizumab.
Jennifer Goossens, Associate Analyst for GBI Research, states: ‘There exists a significant unmet need for improved treatment options across dermatology indications, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles with the long-term use of many available treatments. This is especially true for patients with severe diseases who rely on general immunosuppressive drugs.’
‘There are currently a number of promising biologics in the pipeline for major skin disorders, including atopic dermatitis, acne vulgaris and rosacea, with 17 biologics in Phase III of development. This sizeable number suggests that they could have a considerable impact on treatment algorithms in the dermatology therapy area during the forecast period,’ she added.
In terms of specific products, Regeneron/Sanofi’s dupilumab is the leading candidate to bring about a paradigm shift in the treatment of moderate-to-severe atopic dermatitis. At the same time, the use of older systemic immunosuppressants in dermatology is likely to decrease once biologics for other key indications besides psoriasis enter the market from 2016.
However, GBI Research believes the dermatology space is not likely to experience major shifts in terms of its big players by 2022.
Goossens concludes: ‘Key market players, namely Johnson & Johnson, AbbVie, Amgen, Novartis and Roche, are expected to maintain their strong market shares throughout the forecast period, despite the fact that many of the approaching patent expiries — especially AbbVie’s Humira and Johnson & Johnson’s Remicade — will affect these companies directly.’